A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Verus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin +Etoposide.
Phase of Trial: Phase II/III
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Meclinertant (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SESAME
- Sponsors Sanofi
- 22 Dec 2008 Actual patient number (432) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual end date changed from Apr 2006 to Mar 2006 as reported by Clinicaltrials.gov.
- 13 Sep 2006 New trial record.